FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues

HIV patients will have to wait a while longer for a long-acting viral suppression regimen as the FDA has rejected ViiV Healthcare’s NDA for the monthly injection of cabotegravir and rilpivirine.